Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.425 -0.055 (-1.58%)
Streaming Delayed Price Updated: 9:50 AM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead ↗
This company's growth story is about to get moving with gusto. 
Via The Motley Fool
News headline image
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? ↗
Its revenue is set to grow, and one of its trials is no longer paused. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst ↗
With its first approval in hand, attention is now on the top line. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Could Iovance Biotherapeutics Stock Help You Become a Millionaire? ↗
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio? 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Is Iovance a Buy After Its First Regulatory Win? ↗
Iovance Biotherapeutics has found a new way to treat cancer. 
Via The Motley Fool
News headline image
Why Iovance Biotherapeutics Stock Got Trounced on Thursday ↗
A robust rally ended abruptly with the publication of the company's latest fundamentals. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy? ↗
More gains might be on the way for this high-flying biotech stock. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
3 Stocks Flashing Recent Insider Buying Signals ↗
One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company. 
Via InvestorPlace
News headline image
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Unusual Options Activity For February 22 ↗
 
Via Benzinga
News headline image
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 ↗
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
News headline image
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street ↗
A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof. 
Via The Motley Fool
News headline image
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst ↗
It has good news in hand and plenty of room to grow. 
Via The Motley Fool
News headline image
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value ↗
These two businesses have viable paths to making investors richer -- possibly soon. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.